After a record FY25, the drugmaker sees new growth engines in biologics, vaccines, and devices powering expansion in FY26.

ICICI Securities recommended hold rating on Zydus Lifesciences with a target price of Rs 910 in its research report dated May ...

The identity refresh presents Zydus Wellness as a science-based organisation focused on community and stakeholder engagement.

The company's net profit was at Rs 1,182 crore, with revenue at Rs 5,633 crore and EBITDA margin rising to 26.7 percent, in ...

We are looking at what kind of products, diagnostics or other solutions we can offer to become a well-rounded player in a particular disease area globally.' ...

Zydus Lifesciences Ltd. reported growth in the fourth quarter of fiscal 2025, driven by higher non-recurring components in ...

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

Results: Net profit for the quarter fell 1% from the year-ago period to ₹1,171 crore. The company reported a one-time loss of ...

Ahmedabad-based Zydus Lifesciences Ltd has registered a decline of around 1% in net profit at Rs. 1,170.9 crore during the last quarter of FY25, as compared to Rs. 1,182.3 crore in the same period a ...

Indian drugmaker Zydus Lifesciences reported a higher adjusted fourth-quarter profit on Tuesday, driven by new drug launches in the U.S., its biggest market.

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...

Zydus Lifesciences Limited announced a notable 19% increase in revenue for FY25, with net profits rising to Rs. 47,451 mn.